Center-Authored Papers

Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Pyrrolidines
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Ensrud K, LaCroix AZ, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R et al..  2010.  Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.. Circulation. 122(17):1716-24. Abstract
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J et al..  2010.  Lasofoxifene in postmenopausal women with osteoporosis.. The New England journal of medicine. 362(8):686-96. Abstract
Pyrroles
Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.  2008.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.. PharmacoEconomics. 26(4):329-39. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Hartwell LH, MAGASANIK B.  1964.  THE MECHANISM OF HISTIDASE INDUCTION AND FORMATION IN BACILLUS SUBTILIS.. Journal of molecular biology. 10:105-19.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.  2010.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(21):5260-8. Abstract
Pyrophosphatases
Fishburn J, Hahn S.  2012.  Architecture of the yeast RNA polymerase II open complex and regulation of activity by TFIIF.. Molecular and cellular biology. 32(1):25. Abstract
Pyrimidines
Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S et al..  2017.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(26):3010-3020. Abstract
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond KA, Bramwell VHC, Baker LH, Maki RG et al..  2008.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(4):626-32. Abstract
Radich JP.  2010.  Stem cell transplant for chronic myeloid leukemia in the imatinib era.. Seminars in hematology. 47(4):354-61. Abstract
Radich JP.  2012.  Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.. Cancer. 118(2):300-11. Abstract
Hochhaus A, Müller MC, Radich JP, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim D-W, Lipton JH, Bleickardt E et al..  2009.  Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(9):1628-33. Abstract
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey AE, Flowers MED, Maris MB, Laport GG, Chauncey TR, Lange T et al..  2011.  Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.. Haematologica. 96(8):1113-20. Abstract
Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler VG, Wood C et al..  2011.  Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.. Pediatric blood & cancer. 57(1):56-62. Abstract
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG et al..  2010.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).. Blood. 116(19):3758-65. Abstract
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow JR, Hortobagyi GN, Livingston R.  2008.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.. Clinical breast cancer. 8(6):511-5. Abstract
Hartwell LH.  1970.  Biochemical genetics of yeast.. Annual review of genetics. 4:373-96.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F et al..  2009.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(35):6041-51. Abstract
Chen GL, Arai S, Flowers MED, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB.  2011.  A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.. Blood. 118(15):4070-4078. Abstract
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M et al..  2009.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(6):1054-61. Abstract
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract